FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783740250> ?p ?o ?g. }

• W2783740250 endingPage "63" @default.
• W2783740250 startingPage "52" @default.
• W2783740250 abstract "Recent studies on psoriasis confirmed that interleukin-17 (IL-17) plays a crucial role in the progression of the disease. Inhibition of this cytokine leads to significant improvement in the course of the disease. Russian biotechnology company BIOCAD have developed an innovative drug, a monoclonal antibody against IL-17, BCD-085. The main objective of the phase II study was to determine the optimal therapeutic dose of BCD-085 in patients with moderate-tosevere plaque psoriasis. The efficacy, safety, and pharmacokinetics of the drug have also been investigated.Materials and methods The study was an international multicenter, comparative, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of multiple subcutaneous administration of various doses of BCD-085 to patients with moderate to severe plaque psoriasis. Patients were randomized into 4 groups in 1:1:1:1 ratio: group 1 received BCD-085 at a dose of 40 mg, group 2 – 80 mg, group 3 – 120 mg, and group 4 received placebo. Administration of BCD-085/placebo was performed subcutaneously on day 1 at weeks 0, 1, 2, and then on day 1 at weeks 4, 6, 8, 10.Results All studied doses of BCD-085 demonstrated significant superiority over placebo and high efficacy in the treatment of plaque psoriasis. PASI 75 at week 12 was reached by 92.68% of patients in group 3 (120 mg of BCD-085), 83.33% in group 2 (80 mg of BCD-085), 80.0% in group 1 (40 mg of BCD-085), and 23.08% in group 4 (placebo) (p 0.0001). In the course of the study, the dose-dependent effect of the drug was demonstrated. The drug showed favorable safety profile (no cases of serious adverse events or early withdrawal due to adverse events, no cases of adverse events with 4 grade of severity according to CTCAE 4.03). According to the results of pharmacokinetics study, the drug is characterized by a linear increase in serum BCD-085 concentration, reaching its maximum by the end of the first week of observation, and by slow elimination.Conclusion BCD-085 showed high efficiency, more than 90% of patients reached PASI 75 by the 12th week of treatment, and a favorable safety profile. Based on the results of the phase II study, the optimal therapeutic dose was 120 mg." @default.
• W2783740250 created "2018-01-26" @default.
• W2783740250 creator A5008482641 @default.
• W2783740250 creator A5020595851 @default.
• W2783740250 creator A5026365582 @default.
• W2783740250 creator A5028301750 @default.
• W2783740250 creator A5031853679 @default.
• W2783740250 creator A5057948194 @default.
• W2783740250 creator A5069156171 @default.
• W2783740250 date "2017-10-04" @default.
• W2783740250 modified "2023-10-01" @default.
• W2783740250 title "Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis" @default.
• W2783740250 cites W1508752722 @default.
• W2783740250 cites W1588552166 @default.
• W2783740250 cites W1607447489 @default.
• W2783740250 cites W1644373322 @default.
• W2783740250 cites W1973354423 @default.
• W2783740250 cites W1981177225 @default.
• W2783740250 cites W2001493542 @default.
• W2783740250 cites W2022917731 @default.
• W2783740250 cites W2033275545 @default.
• W2783740250 cites W2040164730 @default.
• W2783740250 cites W2064645845 @default.
• W2783740250 cites W2076456688 @default.
• W2783740250 cites W2085609593 @default.
• W2783740250 cites W2092172066 @default.
• W2783740250 cites W2107432039 @default.
• W2783740250 cites W2123946257 @default.
• W2783740250 cites W2149566497 @default.
• W2783740250 cites W2160247072 @default.
• W2783740250 cites W2171889601 @default.
• W2783740250 cites W2281847379 @default.
• W2783740250 cites W2322390243 @default.
• W2783740250 cites W2549572237 @default.
• W2783740250 cites W2586220284 @default.
• W2783740250 cites W2588887926 @default.
• W2783740250 cites W2591848766 @default.
• W2783740250 doi "https://doi.org/10.25208/0042-4609-2017-93-5-52-63" @default.
• W2783740250 hasPublicationYear "2017" @default.
• W2783740250 type Work @default.
• W2783740250 sameAs 2783740250 @default.
• W2783740250 citedByCount "13" @default.
• W2783740250 countsByYear W27837402502019 @default.
• W2783740250 countsByYear W27837402502020 @default.
• W2783740250 countsByYear W27837402502021 @default.
• W2783740250 countsByYear W27837402502022 @default.
• W2783740250 countsByYear W27837402502023 @default.
• W2783740250 crossrefType "journal-article" @default.
• W2783740250 hasAuthorship W2783740250A5008482641 @default.
• W2783740250 hasAuthorship W2783740250A5020595851 @default.
• W2783740250 hasAuthorship W2783740250A5026365582 @default.
• W2783740250 hasAuthorship W2783740250A5028301750 @default.
• W2783740250 hasAuthorship W2783740250A5031853679 @default.
• W2783740250 hasAuthorship W2783740250A5057948194 @default.
• W2783740250 hasAuthorship W2783740250A5069156171 @default.
• W2783740250 hasBestOaLocation W27837402501 @default.
• W2783740250 hasConcept C112705442 @default.
• W2783740250 hasConcept C126322002 @default.
• W2783740250 hasConcept C142724271 @default.
• W2783740250 hasConcept C16005928 @default.
• W2783740250 hasConcept C168563851 @default.
• W2783740250 hasConcept C204243189 @default.
• W2783740250 hasConcept C204787440 @default.
• W2783740250 hasConcept C27081682 @default.
• W2783740250 hasConcept C2777011040 @default.
• W2783740250 hasConcept C2778690821 @default.
• W2783740250 hasConcept C2780035454 @default.
• W2783740250 hasConcept C2780564577 @default.
• W2783740250 hasConcept C3020604521 @default.
• W2783740250 hasConcept C47348012 @default.
• W2783740250 hasConcept C535046627 @default.
• W2783740250 hasConcept C71924100 @default.
• W2783740250 hasConcept C74172505 @default.
• W2783740250 hasConcept C90924648 @default.
• W2783740250 hasConcept C98274493 @default.
• W2783740250 hasConceptScore W2783740250C112705442 @default.
• W2783740250 hasConceptScore W2783740250C126322002 @default.
• W2783740250 hasConceptScore W2783740250C142724271 @default.
• W2783740250 hasConceptScore W2783740250C16005928 @default.
• W2783740250 hasConceptScore W2783740250C168563851 @default.
• W2783740250 hasConceptScore W2783740250C204243189 @default.
• W2783740250 hasConceptScore W2783740250C204787440 @default.
• W2783740250 hasConceptScore W2783740250C27081682 @default.
• W2783740250 hasConceptScore W2783740250C2777011040 @default.
• W2783740250 hasConceptScore W2783740250C2778690821 @default.
• W2783740250 hasConceptScore W2783740250C2780035454 @default.
• W2783740250 hasConceptScore W2783740250C2780564577 @default.
• W2783740250 hasConceptScore W2783740250C3020604521 @default.
• W2783740250 hasConceptScore W2783740250C47348012 @default.
• W2783740250 hasConceptScore W2783740250C535046627 @default.
• W2783740250 hasConceptScore W2783740250C71924100 @default.
• W2783740250 hasConceptScore W2783740250C74172505 @default.
• W2783740250 hasConceptScore W2783740250C90924648 @default.
• W2783740250 hasConceptScore W2783740250C98274493 @default.
• W2783740250 hasIssue "5" @default.
• W2783740250 hasLocation W27837402501 @default.
• W2783740250 hasLocation W27837402502 @default.
• W2783740250 hasOpenAccess W2783740250 @default.

• next